Vical hopes to proceed with Phase III CMV vaccine trial after positive advice from EMA
This article was originally published in Scrip
Executive Summary
Vical, a US biopharmaceutical company, looks poised to move ahead with designing Phase III trials of its CMV (cytomegalovirus) vaccine, TransVax, after receiving positive scientific advice from the European Medicines Agency. The company is looking for a commercial partner for the vaccine in major markets in the Americas, Europe and Southeast Asia.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.